OSIPECT SYRUP; guaifenesin, terbutaline, diphenhydramine, respiratory tract agents .
ACTIVE-INGREDIENT OF OSIPECT SYRUP
each teaspoonful ( 5 ml ) contains : – terbutaline sulphate 1.5 mg . – diphenhydramine HCL 14 mg . – glyceryl guaiacolate 50 mg . – potassium citrate 50 mg .
INDICATION OF OSIPECT SYRUP
osipect is indicated for the following cases : – bronchodilation ; relief and prevention of bronchospasm in bronchial asthma and other bronchopulmonary disorders in which bronchospasm is a complicated factor . – relief of cough and its congestive symptoms , such as runny nose and sneezing , and in the treatment of hay fever and other allergic conditions affecting the upper respiratory tract . symptomatic relief of catarrh associated with influenze , colds and mild throat infections .
DOSAGE OF OSIPECT SYRUP
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
adults : the starting dose should be 2 teaspoonfuls(10ml) , 3 timesin 24 hours , if necessary to achieve adequate bronchodilation the dose may then be increased to 1 tablespoonfuls ( 15 ml ) , 3 times in 24 hours . -elderly : dosage as adults . – children over 6 years of age : (0.25 ml ) / kg body weight 3 times in a 24 hour period (expressed by 1 teaspoonful 3 times daily ) . renal dysfunction : the dose interval should be extended by a period dependent on glomerular filtration rate (GFR) .
OVER-DOSAGE OF OSIPECT SYRUP
terbutaline : possible symptoms and signs : headache , anxiety , tremor ,nausea , tonic cramp, palpitations , tachycardia . Arrhythmia , a fall in blood pressure sometimes occurs . Laboratory findings : hypokalaemia , hyperglycaemia , and lactic acidosis sometimes occur . treatment : mid and moderate cases : reduce the dose . severe cases : – gastric lavage , administration of activated charcoal . – determination of acid – base balance , blood suger and electrolytes , particularly serum potassium levels . – monitoring of the heart rate and rhythm and blood pressure . – metabolic changes should be corrected .
CONTRA-INDICATION OF OSIPECT SYRUP
hypersensitivity to any of the ingredients . – individuals with severe hypertension or coronary artery disease due to the vasoconstrictor effect of diphenhydramine . – patients current receiving monoamine oxidase inhibitors (MAOls) or those patients who have received treatment with MAOls within the last two weeks . – renal dysfunction venticular arrhythmics and addison’s disease. – diphenhydramine should not be taken by patients with susceptibility to angle closure glaucoma or symptomatic prostatic hypertrophy , unless directed by a doctor . patients with rare hereditary problems of fructose intolerance , glucose-galactose malabsorption or suctase-isomaltase insufficiency . – do not use to make a child sleeply . – do not use with any other products containing diaphenhydramine , even one used in skin .
STORAGE OF OSIPECT SYRUP
store at room temperature (25 – 30 ) ° C .
PACK OF OSIPECT SYRUP
carton box containing a bottle of 120 ml .
OSIPECT SYRUP MANUFACTURED BY
chemical industries development (CID )